A biomarker with significant prognostic potential in cancer and neuronal differentiation

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		1492
IP Type:		Licensable Technology
Title:		A biomarker with significant prognostic potential in cancer and neuronal differentiation
Inventor:		Kirschner, Marc W.
Summary:		MARKETS ADDRESSED: Early applications of the geminin biomarker may focus on breast cancer and lymphoma prognosis. Companies with strong reagent libraries and cellular analysis systems may package Ki67 with geminin for immunohistochemistry-based (breast) and flow-cytometry (lymphoma) prognostics. As an adjunct, geminin also has important research applications for tracking the cell cycle and the transition of proliferating neural progenitors into differentiating neurons (see Developmental Cell, Vol. 9, August, 2005). INNOVATIONS & ADVANTAGES: A nuclear protein known as geminin is proposed as a broadly applicable cancer biomarker. The geminin protein was initially discovered by Kirchner et al. as an inhibitor of DNA synthesis and as a key regulator of genetic stability during chromosomal replication. Recent studies have pointed out a novel, and as of yet unelucidated, role for geminin as an oncogene. These studies have shown consistent upregulation of geminin in a variety of cancers, and have further suggested that geminin has significant clinical utility as both a cancer diagnostic and prognostic.
Tech Type:		Genomics/Proteomics \| Research Reagents \| Genomics/Proteomics
URL:		http://otd.harvard.edu/technologies/tech.php?case=1492
Contact:		Michal Preminger, (617) 432-0920
Organization:		Harvard University

Display all intellectual properties for Kirschner, Marc W.
Display all intellectual properties for Harvard University